These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 19403243

  • 1. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.
    White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, Beebe KL.
    Drug Alcohol Depend; 2009 Jul 01; 103(1-2):37-43. PubMed ID: 19403243
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
    Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE.
    Addiction; 2004 Nov 01; 99(11):1439-49. PubMed ID: 15500597
    [Abstract] [Full Text] [Related]

  • 5. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J.
    Addiction; 2012 Jan 01; 107(1):142-51. PubMed ID: 21749526
    [Abstract] [Full Text] [Related]

  • 6. In-vitro and in-vivo characterization of a buprenorphine delivery system.
    Kleppner SR, Patel R, McDonough J, Costantini LC.
    J Pharm Pharmacol; 2006 Mar 01; 58(3):295-302. PubMed ID: 16536895
    [Abstract] [Full Text] [Related]

  • 7. Rapid detoxification of heroin dependence by buprenorphine.
    Liu ZM, Cai ZJ, Wang XP, Ge Y, Li CM.
    Zhongguo Yao Li Xue Bao; 1997 Mar 01; 18(2):112-4. PubMed ID: 10072959
    [Abstract] [Full Text] [Related]

  • 8. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK, Morris N, Arnold-Reed D, Tait RJ.
    Arch Gen Psychiatry; 2009 Oct 01; 66(10):1108-15. PubMed ID: 19805701
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence.
    Kakko J, von Wachenfeldt J, Svanborg KD, Lidström J, Barr CS, Heilig M.
    Biol Psychiatry; 2008 Jan 15; 63(2):172-7. PubMed ID: 17850768
    [Abstract] [Full Text] [Related]

  • 11. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.
    Daulouède JP, Caer Y, Galland P, Villeger P, Brunelle E, Bachellier J, Piquet JM, Harbonnier J, Leglise Y, Courty P.
    J Subst Abuse Treat; 2010 Jan 15; 38(1):83-9. PubMed ID: 19800758
    [Abstract] [Full Text] [Related]

  • 12. Buprenorphine: an alternative to methadone for heroin dependence treatment.
    Resnick RB, Galanter M, Pycha C, Cohen A, Grandison P, Flood N.
    Psychopharmacol Bull; 1992 Jan 15; 28(1):109-13. PubMed ID: 1609035
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
    Giacomuzzi S, Kemmler G, Ertl M, Riemer Y.
    Subst Use Misuse; 2006 Jan 15; 41(2):223-44. PubMed ID: 16393744
    [Abstract] [Full Text] [Related]

  • 15. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D, Buprenorphine/Naloxone Collaborative Study Group.
    N Engl J Med; 2003 Sep 04; 349(10):949-58. PubMed ID: 12954743
    [Abstract] [Full Text] [Related]

  • 16. Heroin detoxification with a single high dose of buprenorphine.
    Kutz I, Reznik V.
    Isr J Psychiatry Relat Sci; 2002 Sep 04; 39(2):113-9. PubMed ID: 12227226
    [Abstract] [Full Text] [Related]

  • 17. Buprenorphine dosing regime in the management of out-patient heroin withdrawal.
    Lintzeris N.
    Drug Alcohol Rev; 2002 Mar 04; 21(1):39-45. PubMed ID: 12189003
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ, Walsh SL, Bigelow GE, Strain EC.
    Psychopharmacology (Berl); 2006 Dec 04; 189(3):297-306. PubMed ID: 17013637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.